文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

辅助氯胺酮与丁丙诺啡治疗共病重性抑郁障碍与阿片类物质使用障碍:一项评估焦虑症状严重程度与渴求强度的随机双盲临床试验

Adjunctive ketamine vs. buprenorphine in co-occurring major depressive disorder and opioid use disorder: a randomized, double-blind clinical trial assessing anxiety symptom severity and craving intensity.
PubMed 文献 · Trials · 2025-04-17

本研究为随机双盲临床试验,纳入同时符合重性抑郁障碍(MDD)与阿片类物质使用障碍(OUD)诊断标准的个体,随机接受辅助氯胺酮或丁丙诺啡联合标准精神科与成瘾治疗。采用汉密尔顿焦虑量表(HAM-A)和阿片类渴求量表在2小时、24小时和7天评估焦虑症状严重程度与渴求强度。结果显示氯胺酮在给药后数小时内快速大幅降低焦虑症状严重程度并显著降低阿片类渴求强度,丁丙诺啡则表现为数天内焦虑症状逐渐但持续改善,伴随阿片类渴求初始轻度降低后持续减弱。

要点

  • 氯胺酮在给药后数小时内快速且大幅降低焦虑症状严重程度,并显著降低阿片类渴求强度。
  • 丁丙诺啡在数天内逐渐但持续改善焦虑症状,阿片类渴求初始轻度降低后持续减弱。
  • 两种辅助药物联合标准治疗均显示减少焦虑症状与渴求强度的疗效证据。

核心结论

  • 该随机临床试验提供证据支持辅助氯胺酮和丁丙诺啡可减少共病MDD与OUD患者的焦虑症状和渴求强度。

研究设计与样本

  • 随机双盲临床试验,纳入同时符合MDD和OUD诊断标准的个体,随机分配接受辅助氯胺酮或丁丙诺啡联合标准精神科与成瘾治疗。

主要发现

  • 氯胺酮在给药后数小时内快速且大幅降低焦虑症状严重程度,并伴随阿片类渴求强度显著下降。
  • 丁丙诺啡在数天内逐渐但持续改善焦虑症状,阿片类渴求初始轻度降低后持续减弱。

关键数值与推荐

  • 采用汉密尔顿焦虑量表(HAM-A)评估焦虑症状严重程度,采用阿片类渴求量表评估渴求强度,评估时间点为2小时、24小时和7天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The concomitant presence of major depressive disorder (MDD) and opioid use disorder (OUD) poses a formidable clinical challenge, warranting effective interventions that address both psychiatric and addictive components. AIMS: This study sought to compare the efficacy of adjunctive ketamine and buprenorphine in mitigating anxiety symptom severity and craving intensity in individuals with co-occurring MDD and OUD. METHODS: A randomized, double-blind clinical trial was conducted, involving individuals meeting diagnostic criteria for both MDD and OUD. Participants were randomly assigned to receive adjunctive ketamine or buprenorphine, in conjunction with standard psychiatric and addiction treatments. Anxiety symptom severity and craving intensity were assessed using Hamilton Anxiety Rating Scale (HAM-A), and the Opioid Craving Scale after 2 h, 24 h, and 7 days. RESULTS: The findings revealed distinct treatment trajectories, with ketamine demonstrating rapid and substantial reduction in anxiety symptom severity within hours of administration, accompanied by a pronounced decline in opioid craving intensity. In contrast, buprenorphine was associated with a more gradual but sustained improvement in anxiety symptoms over several days, paralleled by a modest initial reduction in opioid craving, followed by persistent attenuation. CONCLUSIONS: In conclusion, this randomized clinical trial provides evidence supporting the efficacy of adjunctive Ketamine and Buprenorphine in reducing anxiety symptoms and craving intensity in patients with co-occurring MDD and OUD. TRIAL REGISTRATION: IRCT20211214053411N1.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Mansoori A, Bazrafshan A, Ahmadi J, et al. Adjunctive ketamine vs. buprenorphine in co-occurring major depressive disorder and opioid use disorder: a randomized, double-blind clinical trial assessing anxiety symptom severity and craving intensity. Trials. 2025. PMID: 40247293. doi:10.1186/s13063-025-08836-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。